Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.
Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback